We develop three core benefits into all OncoLize products compared to the current standard of care products:

  1. Much better at eradicating the tumor

  2. …with far less side-effects

  3. … and fully accessible and affordable

Our products consist of the InGell polymer, with or without standard solution buffers, and drugs well-known to oncology.
Often we will select off-patent Chemo-drugs. These are routinely used to eradicate tumor cells, are fully available, and cheap. At sufficiently high doses they can be very effective on their own, and increasingly in combination therapy. But they are also known to cause serious side-effects due to that same toxic effect on other organs and tissues throughout the body. How to boost efficacy, yet reduce toxicity and side-effects at the same time?

In recent years, we have also formulated and effectivelty delivered so-called Immuno-therapy drugs, which is rapidly becoming an attractive alternative choice of drugs, despite its very high costs. How to make novel drugs more affordable?

Finally, radio-sensitizing drugs can be formulated to increase efficacy of radiation with less energy-exposure. Yet these molecules also cause considerable side-effects as neo-adjuvants. They also often require long lead times before radio-therapy can start while the tumor is progressing. How to shorten that precious time ?

What do we do different…

We encaspulate these drugs inside the InGell polymer-nanoparticles. Then, doctors can inject the liquid formulation through a thin needle or a catheter straight into the tumor. Within seconds, the injected liquid forms a soft, rubber-like macro-gel that stays in place. That is how we localize the drug load to the tumor, to prevent it from spreading to surrounding organs and healthy tissues.

Over time, being days – weeks – months as we design it, the depot gradually degrades layer by layer, releasing the entrapped drugs slowly but surely.

We have measured the following benefits in various pre-clinical models of other applications:

  1. the level of the drug inside the target tissue is 10-100x higher than ever could be achieved through pills, transdermal patches or injections into blood veins
  2. the level of drug outside the target tissue is up to 1000x lower than inside the target tissue, often not measurable anymore within a day, while locally present for weeks on end
  3. The required total drug-load was up to 300x less than via the other routes of administration

In this way, surgeons and oncologists can deliver the required drug dose to the tumor, and keep it there for a fixed period of time. If they can approach it with a long, thin needle or catheter, we can make the product.

Even better, the Hospital Pharmacy can make it overnight with standard equipment and simple mixing and stirring. This allows for personalized medicine dosing and alternative dosing regimes, both in clinical trials and in approved products. Making the formulation is that simple…

But can we treat metastisized tumors in this way?
Yes and no…

  • As long as the doctor can localize the metastisized tumor and approach it with a needle or catheter, he can deliver our drug depot. 
  • Because we have localized the drug to do its work inside the tumor(s), we do not deliver sufficient drug to distant tumors which have not been identified yet or injected…